Kenneth Attie
VP Eli Lilly & Co.
Kenneth Attie’s career at Eli Lilly is marked by significant contributions to the field of biopharmaceuticals. He has held various leadership roles, including Chief Medical Officer, where he has been instrumental in advancing therapeutic programs through regulatory approval. Attie’s expertise spans across multiple indications, with a focus on developing biotherapeutics for obesity and cardiometabolic diseases. His work at Versanis Bio continues to highlight his dedication to advancing innovative therapeutics that address complex medical conditions.
Seminars
Wednesday 15th July 2026
Body Composition Changes During Withdrawal from Weight Loss Medications: Insights from the BELIEVE Trial Extension and Metabolic Implications
2:00 pm
- Comparing semaglutide and bimagrumab, alone or in combination, during 72 weeks treatment and 32 weeks withdrawal to understand actual changes in fat and lean mass by serial DXA measurements
- Quantifying differential effects on visceral fat, subcutaneous fat, and skeletal muscle of incretins and activin pathway inhibitors • Implications for durable vs pharmacologic effects on adipose, muscle, and other tissues and the long-term cardio-metabolic consequences
- Incorporating follow-on studies to track the durability of benefits associated with various weight loss mechanisms and treatment strategies.
